A mathematical model of atherosclerosis with reverse cholesterol transport and associated risk factors

Avner Friedman1, Wenrui Hao

  • 1Department of Mathematics, Mathematical Biosciences Institute, The Ohio State University, Columbus, OH, USA, afriedman@math.osu.edu.

Insights

This study refines a mathematical model for atherosclerosis plaque growth, incorporating reverse cholesterol transport. Model simulations suggest potential therapeutic strategies applicable to humans, offering insights into managing risk factors like high blood pressure and smoking.

Area of Science:

  • Cardiovascular Science
  • Mathematical Biology
  • Pharmacology

Background:

  • Atherosclerosis is a leading cause of death, characterized by arterial plaque buildup.
  • Blood concentrations of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) are key risk factors.
  • Previous mathematical models have explored plaque growth based on LDL and HDL levels.

Purpose of the Study:

  • To refine a mathematical model of atherosclerosis plaque growth by incorporating reverse cholesterol transport.
  • To explore the efficacy of potential drug therapies for plaque regression in mice and extrapolate to humans.
  • To investigate the impact of oxidative stress, hypertension, and smoking on atherosclerosis risk.

Main Methods:

  • Development and refinement of a mathematical model for plaque growth.
  • Inclusion of reverse cholesterol transport mechanisms in the model.
  • Simulation-based exploration of plaque regression in mice and analysis of risk factors.

Main Results:

  • Model simulations suggest that drugs effective in mice may also slow plaque growth in humans.
  • The study explored the influence of oxidative stress, antioxidant deficiency, high blood pressure, and smoking.
  • Strategies for risk reduction in individuals with specific (LDL, HDL) concentrations were proposed.

Conclusions:

  • Refined mathematical models can provide insights into atherosclerosis progression and regression.
  • Therapeutic interventions tested in mice may hold promise for human application.
  • Understanding and mitigating risk factors like hypertension and smoking are crucial for managing atherosclerosis.

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.3K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
634
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.0K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
395
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
838